Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

The SHP-1 expression is associated with cytokines and psychopathological status in unmedicated first episode schizophrenia patients.

Pesce M, Ferrone A, Rizzuto A, Tatangelo R, Iezzi I, Ladu S, Franceschelli S, Speranza L, Patruno A, Felaco M, Grilli A.

Brain Behav Immun. 2014 Oct;41:251-60. doi: 10.1016/j.bbi.2014.04.008. Epub 2014 Apr 30.

PMID:
24793756
2.

EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma.

Pellegrino R, Calvisi DF, Neumann O, Kolluru V, Wesely J, Chen X, Wang C, Wuestefeld T, Ladu S, Elgohary N, Bermejo JL, Radlwimmer B, Zörnig M, Zender L, Dombrowski F, Evert M, Schirmacher P, Longerich T.

Hepatology. 2014 May;59(5):1886-99. doi: 10.1002/hep.26954. Epub 2014 Mar 27.

3.

Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value.

Evert M, Frau M, Tomasi ML, Latte G, Simile MM, Seddaiu MA, Zimmermann A, Ladu S, Staniscia T, Brozzetti S, Solinas G, Dombrowski F, Feo F, Pascale RM, Calvisi DF.

Br J Cancer. 2013 Nov 12;109(10):2654-64. doi: 10.1038/bjc.2013.606. Epub 2013 Oct 17.

4.

Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma.

Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, Ladu S, Singer S, Pinna F, Gretz N, Sticht C, Tomasi ML, Delogu S, Evert M, Fan B, Ribback S, Jiang L, Brozzetti S, Bergmann F, Dombrowski F, Schirmacher P, Calvisi DF, Breuhahn K.

Gastroenterology. 2013 Jun;144(7):1530-1542.e12. doi: 10.1053/j.gastro.2013.02.009. Epub 2013 Feb 16.

5.

Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways.

Wang C, Delogu S, Ho C, Lee SA, Gui B, Jiang L, Ladu S, Cigliano A, Dombrowski F, Evert M, Calvisi DF, Chen X.

J Hepatol. 2012 Sep;57(3):577-83. doi: 10.1016/j.jhep.2012.04.026. Epub 2012 May 19.

6.

V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis.

Evert M, Calvisi DF, Evert K, De Murtas V, Gasparetti G, Mattu S, Destefanis G, Ladu S, Zimmermann A, Delogu S, Thiel S, Thiele A, Ribback S, Dombrowski F.

Hepatology. 2012 May;55(5):1473-84. doi: 10.1002/hep.25600. Epub 2012 Apr 4.

PMID:
22271091
7.

AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.

Ho C, Wang C, Mattu S, Destefanis G, Ladu S, Delogu S, Armbruster J, Fan L, Lee SA, Jiang L, Dombrowski F, Evert M, Chen X, Calvisi DF.

Hepatology. 2012 Mar;55(3):833-45. doi: 10.1002/hep.24736. Epub 2011 Dec 19.

8.

Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53.

Calvisi DF, Simile MM, Ladu S, Frau M, Evert M, Tomasi ML, Demartis MI, Daino L, Seddaiu MA, Brozzetti S, Feo F, Pascale RM.

Hepatology. 2011 Apr;53(4):1226-36. doi: 10.1002/hep.24174.

PMID:
21480327
9.

Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.

Frau M, Ladu S, Calvisi DF, Simile MM, Bonelli P, Daino L, Tomasi ML, Seddaiu MA, Feo F, Pascale RM.

J Hepatol. 2011 Jul;55(1):111-9. doi: 10.1016/j.jhep.2010.10.031. Epub 2010 Dec 7.

PMID:
21419759
10.

Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.

Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, Brozzetti S, Staniscia T, Chen X, Dombrowski F, Evert M.

Gastroenterology. 2011 Mar;140(3):1071-83. doi: 10.1053/j.gastro.2010.12.006. Epub 2010 Dec 11.

11.

Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer.

Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM, Thorgeirsson SS.

J Hepatol. 2011 Feb;54(2):311-9. doi: 10.1016/j.jhep.2010.06.036. Epub 2010 Sep 7.

12.

Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis.

Lee SA, Ladu S, Evert M, Dombrowski F, De Murtas V, Chen X, Calvisi DF.

Hepatology. 2010 Aug;52(2):506-17. doi: 10.1002/hep.23681.

13.

Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma.

Pellegrino R, Calvisi DF, Ladu S, Ehemann V, Staniscia T, Evert M, Dombrowski F, Schirmacher P, Longerich T.

Hepatology. 2010 Mar;51(3):857-68. doi: 10.1002/hep.23467.

PMID:
20112253
14.

SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis.

Calvisi DF, Ladu S, Pinna F, Frau M, Tomasi ML, Sini M, Simile MM, Bonelli P, Muroni MR, Seddaiu MA, Lim DS, Feo F, Pascale RM.

Gastroenterology. 2009 Nov;137(5):1816-26.e1-10. doi: 10.1053/j.gastro.2009.08.005. Epub 2009 Aug 15.

PMID:
19686743
15.

The degradation of cell cycle regulators by SKP2/CKS1 ubiquitin ligase is genetically controlled in rodent liver cancer and contributes to determine the susceptibility to the disease.

Calvisi DF, Pinna F, Ladu S, Muroni MR, Frau M, Demartis I, Tomasi ML, Sini M, Simile MM, Seddaiu MA, Feo F, Pascale RM.

Int J Cancer. 2010 Mar 1;126(5):1275-81. doi: 10.1002/ijc.24650.

16.

Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC.

Calvisi DF, Pinna F, Ladu S, Pellegrino R, Simile MM, Frau M, De Miglio MR, Tomasi ML, Sanna V, Muroni MR, Feo F, Pascale RM.

Gut. 2009 May;58(5):679-87. doi: 10.1136/gut.2008.152652. Epub 2009 Jan 9.

PMID:
19136513
17.

E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.

Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS.

Gastroenterology. 2008 Oct;135(4):1322-32. doi: 10.1053/j.gastro.2008.07.012. Epub 2008 Jul 17.

18.

Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease.

Calvisi DF, Pinna F, Ladu S, Pellegrino R, Muroni MR, Simile MM, Frau M, Tomasi ML, De Miglio MR, Seddaiu MA, Daino L, Sanna V, Feo F, Pascale RM.

Carcinogenesis. 2008 Aug;29(8):1639-47. doi: 10.1093/carcin/bgn155. Epub 2008 Jun 25.

PMID:
18579559
19.

Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma.

Calvisi DF, Pinna F, Meloni F, Ladu S, Pellegrino R, Sini M, Daino L, Simile MM, De Miglio MR, Virdis P, Frau M, Tomasi ML, Seddaiu MA, Muroni MR, Feo F, Pascale RM.

Cancer Res. 2008 Jun 1;68(11):4192-200. doi: 10.1158/0008-5472.CAN-07-6157.

20.

Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.

Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS.

J Clin Invest. 2007 Sep;117(9):2713-22.

21.

Altered methionine metabolism and global DNA methylation in liver cancer: relationship with genomic instability and prognosis.

Calvisi DF, Simile MM, Ladu S, Pellegrino R, De Murtas V, Pinna F, Tomasi ML, Frau M, Virdis P, De Miglio MR, Muroni MR, Pascale RM, Feo F.

Int J Cancer. 2007 Dec 1;121(11):2410-20.

22.

Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS.

Gastroenterology. 2006 Apr;130(4):1117-28.

PMID:
16618406
23.

Activation of the canonical Wnt/beta-catenin pathway confers growth advantages in c-Myc/E2F1 transgenic mouse model of liver cancer.

Calvisi DF, Conner EA, Ladu S, Lemmer ER, Factor VM, Thorgeirsson SS.

J Hepatol. 2005 Jun;42(6):842-9. Epub 2005 Apr 8.

PMID:
15885355
24.

Vitamin E down-modulates iNOS and NADPH oxidase in c-Myc/TGF-alpha transgenic mouse model of liver cancer.

Calvisi DF, Ladu S, Hironaka K, Factor VM, Thorgeirsson SS.

J Hepatol. 2004 Nov;41(5):815-22.

PMID:
15519655
25.

Disregulation of E-cadherin in transgenic mouse models of liver cancer.

Calvisi DF, Ladu S, Conner EA, Factor VM, Thorgeirsson SS.

Lab Invest. 2004 Sep;84(9):1137-47.

26.

Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice.

Calvisi DF, Factor VM, Ladu S, Conner EA, Thorgeirsson SS.

Gastroenterology. 2004 May;126(5):1374-86.

PMID:
15131798
27.

Activation of beta-catenin provides proliferative and invasive advantages in c-myc/TGF-alpha hepatocarcinogenesis promoted by phenobarbital.

Calvisi DF, Ladu S, Factor VM, Thorgeirsson SS.

Carcinogenesis. 2004 Jun;25(6):901-8. Epub 2004 Jan 23.

PMID:
14742323
28.

Chromosome mapping of multiple loci affecting the genetic predisposition to rat liver carcinogenesis.

De Miglio MR, Pascale RM, Simile MM, Muroni MR, Calvisi DF, Virdis P, Bosinco GM, Frau M, Seddaiu MA, Ladu S, Feo F.

Cancer Res. 2002 Aug 1;62(15):4459-63.

29.
30.

Depletion of cortical allopregnanolone potentiates stress-induced increase in cortical dopamine output.

Dazzi L, Serra M, Vacca G, Ladu S, Latrofa A, Trapani G, Biggio G.

Brain Res. 2002 Apr 5;932(1-2):135-9.

PMID:
11911871
31.
32.
33.

Inhibition of stress- or anxiogenic-drug-induced increases in dopamine release in the rat prefrontal cortex by long-term treatment with antidepressant drugs.

Dazzi L, Spiga F, Pira L, Ladu S, Vacca G, Rivano A, Jentsch JD, Biggio G.

J Neurochem. 2001 Feb;76(4):1212-20.

Supplemental Content

Support Center